Wall Street brokerages predict that Sol Gel Technologies Ltd (NASDAQ:SLGL) will post earnings of ($0.22) per share for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for Sol Gel Technologies’ earnings, with estimates ranging from ($0.25) to ($0.20). Sol Gel Technologies reported earnings of ($0.40) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 45%. The business is scheduled to report its next earnings results on Tuesday, November 12th.

According to Zacks, analysts expect that Sol Gel Technologies will report full year earnings of ($0.99) per share for the current financial year, with EPS estimates ranging from ($1.18) to ($0.85). For the next financial year, analysts anticipate that the company will post earnings of ($0.92) per share, with EPS estimates ranging from ($1.12) to ($0.62). Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that that provide coverage for Sol Gel Technologies.

Sol Gel Technologies (NASDAQ:SLGL) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.26) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.32) by $0.06. The firm had revenue of $7.79 million for the quarter, compared to the consensus estimate of $7.00 million. Sol Gel Technologies had a negative net margin of 300.12% and a negative return on equity of 67.88%.

SLGL has been the subject of several recent analyst reports. Zacks Investment Research downgraded shares of Sol Gel Technologies from a “buy” rating to a “hold” rating in a research report on Friday, July 19th. HC Wainwright raised their price target on shares of Sol Gel Technologies from $21.00 to $23.00 and gave the stock a “buy” rating in a research note on Tuesday, July 9th. Finally, ValuEngine lowered shares of Sol Gel Technologies from a “buy” rating to a “hold” rating in a report on Thursday, August 1st.

Several hedge funds have recently added to or reduced their stakes in the company. Delek Group Ltd. raised its stake in shares of Sol Gel Technologies by 5.2% during the second quarter. Delek Group Ltd. now owns 1,545,497 shares of the company’s stock valued at $13,750,000 after purchasing an additional 76,585 shares in the last quarter. Clal Insurance Enterprises Holdings Ltd bought a new stake in shares of Sol Gel Technologies during the first quarter valued at about $406,000. Steward Partners Investment Advisory LLC bought a new stake in shares of Sol Gel Technologies during the second quarter valued at about $70,000. BlackRock Inc. raised its stake in shares of Sol Gel Technologies by 104.6% during the second quarter. BlackRock Inc. now owns 10,753 shares of the company’s stock valued at $98,000 after purchasing an additional 5,497 shares in the last quarter. Finally, Invesco Ltd. raised its stake in shares of Sol Gel Technologies by 12.8% during the second quarter. Invesco Ltd. now owns 13,052 shares of the company’s stock valued at $119,000 after purchasing an additional 1,483 shares in the last quarter. 19.88% of the stock is owned by institutional investors and hedge funds.

Shares of NASDAQ:SLGL traded up $0.01 during midday trading on Monday, hitting $8.35. The company has a fifty day moving average of $8.80 and a 200-day moving average of $8.20. The company has a market cap of $158.01 million, a price-to-earnings ratio of -4.64 and a beta of 0.62. Sol Gel Technologies has a 12-month low of $5.41 and a 12-month high of $11.36. The company has a current ratio of 8.00, a quick ratio of 8.00 and a debt-to-equity ratio of 0.01.

About Sol Gel Technologies

Sol-Gel Technologies Ltd., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include TWIN and SIRS-T, which has completed Phase II clinical trials for the treatment of acne vulgaris; and VERED that has completed Phase II clinical trials for the treatment of papulopustular rosacea.

See Also: Trading Penny Stocks

Get a free copy of the Zacks research report on Sol Gel Technologies (SLGL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Sol Gel Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sol Gel Technologies and related companies with MarketBeat.com's FREE daily email newsletter.